Johnson & Johnson Expands U.S. Footprint with More Than $1 Billion Investment in Next Generation Cell Therapy Manufacturing Facility in Pennsylvania
Thursday, February 19, 2026
Johnson & Johnson has announced an investment of more than $1 billion to build a next-generation cell therapy manufacturing plant in Montgomery County, Pennsylvania. The new site will expand the company’s manufacturing capacity in the United States and support its portfolio and pipeline of treatments for cancer, immune-mediated and neurological diseases.
The facility will focus on advanced cell therapy production and forms part of the company’s broader strategy to strengthen domestic manufacturing. It will also support workforce development through training in advanced technologies used in modern biomanufacturing. Once fully operational, the plant is expected to create more than 500 skilled jobs. In addition, more than 4,000 construction roles are anticipated during site development.
Pennsylvania officials stated that the investment reflects the state’s growing position in life sciences and advanced manufacturing. The project is expected to contribute to job creation, regional economic growth and the expansion of healthcare innovation in the area.
Johnson & Johnson already has a significant presence across Pennsylvania, with ten facilities covering more than two million square feet. These sites support manufacturing, research, distribution and office operations. The company’s total annual economic impact in the state is estimated at approximately $10 billion.
The announcement forms part of Johnson & Johnson’s previously outlined plan to invest $55 billion in manufacturing, research and development, and technology across the United States through early 2029.
Source: businesswire.com
